Aims: Research on developing targeted delivery of anticancer drugs for the treatment of
hepatocellular carcinoma (HCC) is ongoing. This study aimed to synthesize nanoliposomes modified
by glycyrrhetinic acid (GA) and ferric tetroxide (Fe3O4) for targeted delivery of paclitaxel for
selective and specific therapy of HCC.
Objective: During this project, GA and Fe3O4 were used to jointly modify the active targeting and
magnetic orientation of paclitaxel nanoliposomes for enhanced targeting of HCC to improve the efficacy,
while reducing the systemic toxicity and side effects of the drug.
Methods: In this study, liposomes were prepared utilizing a thin film dispersion method, in which
the average particle size of GA/Fe3O4-PTX-LP was 148.9 ± 2.3 nm, and the average Zeta potential
was -23.2 ± 3 mV. Based on TEM characterization, GA/Fe3O4-PTX-LP is a closed particle with bilayer
membranes. In vitro release assessments of the drug indicated that the release of GA/Fe3O4-
PTX-LP was sustained.
Results: In vitro cell tests have demonstrated that GA/Fe3O 4-PTX-LP can inhibit the proliferation,
affect the morphology, migration and invasion, and interfere with the cycle of HCC cells. Uptake
tests have confirmed that GA/Fe3O4-PTX-LP can promote the uptake of the drug in HCC
Conclusion: In vivo targeting experiments have shown that GA/Fe3O4-PTX-LP has a strong ability
to target tumors. In vivo antitumor assessments have proven that GA/Fe3O4-PTX-LP can inhibit
tumor growth without obvious toxicity. This project provides a promising nano-targeted drug delivery
system for the treatment of HCC.